MindMed commences "Project Angie": psychedelic drug R&D aimed at treating pain, involving psychedelics including LSD.
Why Smaller Psychedelics Companies Should Start Catching Up To The Sector Leaders
Psychedelic stocks have become extremely concentrated -- like other sectors. Here's why we see that changing in this sector.
Optimi Health Partnership with Numinus Wellness Provides Update on First All-Natural Psilocybin Protocol
Optimi Health announces its product development agreement with Numinus Wellness is advancing toward a human trial.
Psyched Wellness Signs Supply Agreement for Amanita Muscaria
Psyched Wellness has contracted with a Lithuanian company to obtain 200 kgs of Amanita muscaria mushroom caps.
Novamind Doubles in Size, Adds Four New Psychedelic Mental Health Clinics
Novamind is doubling its Cedar Psychiatry network from four to eight locations, estimating a 325% increase in patient visits.
Field Trip Health Ltd. Announces Opening of Psychedelic-Enhanced Therapy Center in Houston; Locations of Next 5 Field Trip Health Centers ($FTRP, $FTRPF)
Field Trip announces the opening of its 5th new U.S. mental health clinic in Houston.
Mydecine Reports Full Year 2020 Financial Results and Provides Business Update
Mydecine reports that it's Phase IIa clinical trial is underway at three sites. Net loss for the year of CAD$26.9 million. Current cash ~CAD$30 million.
Numinus Wellness Q2 2021 Results Highlighted by $17.25 Million Financing, Mindspace Wellbeing Acquisition and Clinical Trial Collaboration with MAPS PBC
Numinus reports its Q2 2021 results. Cash balance of CAD$28.5 million. Net loss of CAD$4.2 million.
The NEXT Psychedelic Stock To Uplist On The NASDAQ?
MindMed Inc has become the first psychedelics company to successfully uplist to the NASDAQ. Who will be the second...???
Small Pharma Completes Reverse Take-Over Transaction
UK-based Small Pharma Inc prepares to go public on the TSXV via RTO, having raised CAD$58 million for its qualifying transaction
MINDCURE Shares Update on Strong Financial Position, Near Term Revenue Drivers and Timeline for iSTRYM's Market Launch, Delivering Mental Wealth
MINDCURE updates investors on key elements of its business model, including its iSTRYM digital therapeutics platform and its emerging TBI research.
Wesana Health and Debut Announce Receipt of Conditional Approval for CSE Listing
Wesana Health obtains conditional approval from the CSE to commence trading, via RTO with Debut Diamonds (CSE:DDI).
